The concentration of selected cancer markers (TPA, TPS, CYFRA 21-1, CEA) in workers occupationally exposed to arsenic (As) and some heavy metals (Pb, Cd) during a two-year observation study

International Journal of Occupational Medicine and Environmental Health

Volumn 20, Issue 3, 2007, Pages 229-239

  Szymańska Chabowska, Anna ^a,b   Antonowicz Juchniewicz, Jolanta ^a   Andrzejak, Ryszard ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE   (Poland)

Author keywords

Arsenic; Cancer markers; Heavy metals; Occupational exposure

Indexed keywords

ARSENIC; CADMIUM; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; HEAVY METAL; LEAD; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; SMOKING; STATISTICAL SIGNIFICANCE; TOXICITY TESTING; URINALYSIS;

EID: 35348907322     PISSN: 12321087     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10001-007-0026-0     Document Type: Article

References (30)

1. Rossman TG. Metal mutagenesis. Hand Exp Pharm 1995;115:373-409.
2. Magos L. Epidemiological and experimental aspects of metal carcinogenesis: physiochemical properties, kinetics and the active species. Environ Health Perspect 1991;95:157-89.
3. Bettley FR, O'Shea JA. The absorption of arsenic and its relation to carcinoma. Br J Dermatol 1975;92:563-9.
4. Lerda D. Sister-chromatid exchange (SCE) among individuals chronically exposed toarsenic in drinking water. Mutat Res1994;312:111-20.
5. Morin ChI, Huot J. Recent advances in stress signaling in cancer. Cancer Res 2004;64:1893-8.
6. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of Action of Arsenic Trioxide. Cancer Res 2002;62:3893-903.
7. Bernstam L, Nriagu J. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 2000;3(4):293-322.
8. Beckman L, Nordenson I. Interaction between some common genotoxic agents. Hum Hered 1986;36:397-401.
9. Liu SX, Athar M, Lippai I, Waldren C, Hei TK. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 2001;98(4):1643-8.
10. Santra A, Maiti A, Chowdhury A, Mazumder DN. Oxidative stress in liver of mice exposed toarsenic-contaminated water. Indian J Gastroenterol 2000;19(3):112-5.
11. General assessment of toxicological hazard from cadmium exposure in Poland. Report of the Toxicology Committee of the Sanitary and Epidemiologic Council. Med Pr1995;5(Suppl. 5):7-23 [in Polish].
12. Hurwitz M, Sawicki M, Samara G, Passaro E. Diagnostic and prognostic molecular markers in cancer. Am J Surg 1992;164:299-306.
13. Senn HJ, Drings P, Glaus A, Schiess A. Biochemical tumour markers. Kompendium Onkologii. Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 1995. p. 35-50.
14. Gisterek I. Clinically useful tumor markers. International Intensive Course of Oncology, Erasmus 1999;99:211-21.
15. Szymendera JJ, Góźdź SS. The role of circulating tumour markers in the diagnostics and treatment monitoring in cancer patients. Nowotwory 1995;45:369-83 [in Polish].
16. Jakubowski M, Trzcińska-Ochocka M, Raźniewska G. Biological monitoring of occupational and environmental exposure tometals: determination methods and result interpretation. Łódź: Oficyna Wydawnicza IMP; 2000 [in Polish].
17. Jakubowski M, Kabata J, Kalinowski L, Szczepańska-Konkel M, Angielski S. Laboratory testing in everyday practice. Reference values and result interpretation. Gdańsk: MAKmed; 1993 [in Polish].
18. Piomelli S. A micromethod for free erythrocyte porphyrins: the FEP test. J Lab Clin Med 1973;81:932-40.
19. Lutz W, Krajewska B. Tumour markers and their role in prevention of occupational cancer Pol Tyg Lek 1990;T.XLV(32-3): 643-6 [in Polish].
20. Ditzel HJ, Strik MC, Larsen MK, Willis AC, Waseem A, Kejling K et al. Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J Biol Chem 2002;277(24):21712-22.
21. Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 2003;123:2001-6.
22. Mohanty SK, Dey P. Serous effusions: diagnosis of malignancy beyond cytomorphology. an analytic review. Postgrad Med J 2003;79:569-74.
23. Dittadi R, Coradini D, Meo S, Pirronello E, Daidone MG, Gion M. Tissue polypeptide antigen as a putative indicator of apoptosis. Clin Chem 1998;44:2002-3.
24. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53(1):61-6.
25. Huang MS, Jong SB, Tsai MS, Lin MS, Chong IW, Lin HC, et al. Comparison of cytokeratin fragment 19 (CYFRA21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 1997;91(3):135-42.
26. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in non-small cell lung cancer. Chest 2003;124:622-32.
27. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1 and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-7.
28. Kramer G, Erdal HJMM, Mertens H, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
29. Salama G, Miedouge M, Rouzaud P, Mauduyt MA, Pujazon MC, Vincent C, et al. Evaluation of pleural CYFRA 21-1 and CEA in the diagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-6.
30. Kulpa J, Wójcik E, Radkowski A, Stasik Z. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res 2000;20:5035-40.